OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology. Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)….
Everads News
December 2025
Everads Technology Featured in 4 Oral Presentations at FLORetina 2025
​
4 presentations at the FLORetina congress held December 4th – 7th 2025 in Florence, Italy, featured the Everads Injector and highlighted the differentiated approach of Everads’ novel suprachoroidal delivery technology. Dr. David Almeida reviewed recently published data evaluating the distribution achieved with the Everads Injector in a human cadaver NRSS model. Dr. Quan Dong Nguyen shared highlights from an ongoing gene therapy study of VV-14295 in adults with geographic atrophy which is being delivered suprachoroidally using the Everads Injector. Dr. Yoreh Barak presented full results from a first in human clinical study using the Everads platform. Lastly, Dr. Gareth Mercer highlighted a non-clinical study evaluating the Everads Injector for suprachoroidal buckling in retinal detachment repair.
November 2025
Everads @ OIS XV
​
Our CEO, Moshe Weinstein, represented Everads at the Ophthalmology Innovation Source (OIS) 15th annual conference held in San Diego on November 21st-22nd (https://ois.net/ois-xv-presenting-companies/ ). Moshe shared updates on Everads’ suprachoroidal delivery injector and highlights from the recently completed clinical trial. Read more for a video of the presentation.
December 2025
Everads Showcased in the Rising Retina Innovation Companies Session at Eyenovate
​
Everads was selected to present its suprachoroidal delivery platform at the Eyenovate conference held adjacent to FLORetina. Dr. Keren Mano Tamir, Vice President of Medical at Everads, presented an overview of the Everads technology and how its novel approach enables a rapid and broad distribution throughout the suprachoroidal space. Reach out via the contact link to request a copy of the presentation.
September 2025
Human Cadaver Study Highlights Effectiveness of Everads Suprachoroidal Injector
​
A recent study published in Translational Vision Science & Technology (TVST) demonstrates that the Everads Suprachoroidal Injector achieves consistent and reproducible spread throughout the suprachoroidal space in a human cadaver model.
December 2025
Everads Presents an Overview of Suprachoroidal Delivery at the Hanson Wade Gene Therapy for Ophthalmic Disorders conference.
​
Everads was invited to present at the 6th Annual Gene Therapy for Ophthalmic Disorders conference held in Raleigh, NC on December 2-4th. At the conference, Everads’ CEO, Moshe Weinstein, delivered a presentation titled Utilizing Suprachoroidal Delivery Technologies to Optimize Gene Therapy Targeting. The presentation highlighted the Everads Injector’s consistent and reproducible spread throughout the suprachoroidal space, as well as data showing the ability to achieve transduction throughout the SCS in NHPs, including the macula, using various AAVs delivered with the Everads Injector. Reach out via the contact link above to request a copy of the presentation.
